Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Study results from Uppsala University update understanding of cancer gene therapy
May 6th, 2008
"Conditionally replicating adenoviruses are developing as a complement to traditional cancer therapies. Ad[ I/PPT-E1A] is an E1B/E3-deleted virus that replicates exclusively in prostate cells, since the expression of E1A is controlled by the recombinant 1.4 kb prostate-specific PPT promoter," scientists in Uppsala, Sweden report. "The transcriptional integrity of PPT is maintained by the 3.0 kb mouse H19 insulator that was introduced directly upstream of the PPT sequence. In order to increase the cloning capacity to be able to reintroduce E3 sequences in the 35.7 kb Ad[ I/PPT- E1A] genome, various shorter insulators were examined in a luciferase reporter gene assay. It...
Source: Cancer Weekly (2008-05-06)
|
